AR108813A1 - Uso de la forma básica de la eritropoyetina humana recombinante en el tratamiento de pacientes con ataxia espinocerebelosa con mutaciones del tipo repeticiones cag - Google Patents

Uso de la forma básica de la eritropoyetina humana recombinante en el tratamiento de pacientes con ataxia espinocerebelosa con mutaciones del tipo repeticiones cag

Info

Publication number
AR108813A1
AR108813A1 ARP170101680A ARP170101680A AR108813A1 AR 108813 A1 AR108813 A1 AR 108813A1 AR P170101680 A ARP170101680 A AR P170101680A AR P170101680 A ARP170101680 A AR P170101680A AR 108813 A1 AR108813 A1 AR 108813A1
Authority
AR
Argentina
Prior art keywords
treatment
basic form
mutations
recombinant human
type
Prior art date
Application number
ARP170101680A
Other languages
English (en)
Inventor
Rodrguez Daise Jimnez
Matilla Lien Lpez
Prez Daniel Jay
Triana Consuelo Gonzlez
Casaa Patricia Hernndez
Snchez Ricardo Ortega
Test Iliana Mara Sosa
Labrada Roberto Rodrguez
Rodrguez Julio Csar Garca
Prez Luis Clodoaldo Velzquez
Gonzlez Daniel Enrique Amaro
Original Assignee
Ct Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Inmunologia Molecular filed Critical Ct Inmunologia Molecular
Publication of AR108813A1 publication Critical patent/AR108813A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/746—Erythropoetin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)

Abstract

Uso de composiciones farmacéuticas que tienen como principio activo a la forma básica de la eritropoyetina humana recombinante (rhEPO) y que se administran por vía nasal en el tratamiento de la Ataxia Espinocerebelosa (SCA) con mutaciones del tipo repeticiones CAG, particularmente a la SCA de tipo 2. Método de estratificación de pacientes como respondedores o no al tratamiento con la forma básica de la rhEPO. Reivindicación 1: Uso de la forma básica de la eritropoyetina humana recombinante (rhEPO) para la manufactura de una formulación para administración nasal, útil en el tratamiento de la ataxia espinocerebelosa (SCA) con mutaciones de tipo repeticiones CAG.
ARP170101680A 2016-06-20 2017-06-19 Uso de la forma básica de la eritropoyetina humana recombinante en el tratamiento de pacientes con ataxia espinocerebelosa con mutaciones del tipo repeticiones cag AR108813A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20160092 2016-06-20

Publications (1)

Publication Number Publication Date
AR108813A1 true AR108813A1 (es) 2018-09-26

Family

ID=59362857

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101680A AR108813A1 (es) 2016-06-20 2017-06-19 Uso de la forma básica de la eritropoyetina humana recombinante en el tratamiento de pacientes con ataxia espinocerebelosa con mutaciones del tipo repeticiones cag

Country Status (7)

Country Link
US (1) US20210060127A1 (es)
EP (1) EP3473264B1 (es)
AR (1) AR108813A1 (es)
AU (1) AU2017282933B2 (es)
ES (1) ES2878327T3 (es)
TW (1) TW201808326A (es)
WO (1) WO2017220053A1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23317A1 (es) 2005-07-22 2008-10-22 Ct De Investigacia N Y Desarro Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central

Also Published As

Publication number Publication date
ES2878327T3 (es) 2021-11-18
EP3473264A1 (en) 2019-04-24
EP3473264B1 (en) 2021-05-12
AU2017282933A1 (en) 2019-02-07
AU2017282933B2 (en) 2024-03-21
TW201808326A (zh) 2018-03-16
WO2017220053A1 (es) 2017-12-28
US20210060127A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
MX2019010171A (es) Composiciones, articulos de fabricacion y metodos relacionados con la dosificacion en la terapia celular.
BR112015025464A2 (pt) coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
CY1123485T1 (el) Συνθεσεις και μεθοδοι για τη θεραπεια νοσων
BR112018004536A2 (pt) peptídeos de endereçamento à cartilagem
ECSP14016014A (es) Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardíaca
CO7151487A2 (es) Formulación de anticuerpos
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
UY35586A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CL2015002835A1 (es) Nuevos derivados de piridina
BR112012013164A2 (pt) composições farmacêuticas para o estímulo de células-tronco
CL2020000019A1 (es) Agentes de iarn para la inhibición de la expresión de alfa-enac y métodos de uso.
BR112017016087A2 (pt) formulações para coxim articular adiposo e métodos de uso das mesmas
AR114324A1 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
AR114325A1 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
ES2656913T3 (es) Endrogenina A y agentes antineoplásicos para el tratamiento de tumores quimiosensibles o quimiorresistentes
AR103415A1 (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2
AR114323A1 (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico
EA201591415A1 (ru) Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии
AR108813A1 (es) Uso de la forma básica de la eritropoyetina humana recombinante en el tratamiento de pacientes con ataxia espinocerebelosa con mutaciones del tipo repeticiones cag
PE20171340A1 (es) Composicion farmaceutica para el tratamiento de enfermedades gastrointestinales
ECSP15005163A (es) Composiciones líquidas orales pediátricas que contienen nepadutant
PE20080674A1 (es) Composiciones terapeuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidermico
AR112754A1 (es) AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE a-ENaC Y MÉTODOS DE USO
BR112015030751A2 (pt) formas polimórficas de icotinib e usos das mesmas
EA201592261A1 (ru) Фармацевтические композиции, включающие агомелатин в форме сокристаллов агомелатина с органической кислотой

Legal Events

Date Code Title Description
FB Suspension of granting procedure